Article Details - Overview
New Developments in Targeted Therapy for Gastrointestinal Stromal Tumors
Oncology Briefings Vol. 7, No. 1
This activity is not sanctioned by, nor a part of, the 2009 Gastrointestinal Cancers Symposium.
Release Date: March 31, 2009
Expiration Date: March 31, 2010
Publication Overview
Authors
Medical writer: Timothy Quill, PhD; Reviewed by: Jean-Yves Blay, MD, PhD
Overview and Purpose
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor type of the gastrointestinal tract; approximately 6000 new cases are diagnosed in the United States each year. Activating mutations in the c-Kit receptor tyrosine kinase (TK) are the predominant cause of GIST, and the integration of TK-targeted agents into GIST treatment has markedly changed the management of these tumors. The use of TK inhibitors (TKIs) as therapy for GIST continues to evolve from treatment for metastatic disease to adjuvant therapy following surgical resection. Data on mutation status and efficacy that are relevant to the planning of an optimal personalized treatment course are emerging. Other novel agents under investigation are also expanding treatment options for patients with GIST.
The purpose of this activity is to inform physicians of new developments in the use of targeted therapies in patients with both resectable and unresectable GIST.
Target Audience
This activity is intended for medical oncologists involved in the care of patients with gastrointestinal stromal tumors (GIST). No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Learning Objectives
Upon completion of this educational activity, you should be able to:
- Evaluate the efficacy and safety of TKIs in the adjuvant setting for patients with high-risk resectable GIST
- Discuss the impact of specific mutations in c-Kit on the efficacy of treatment with small-molecule TKIs
- Assess the treatment options for patients with metastatic GIST following progression on initial therapy with a TKI
Instructions for Participation
This online activity provides a maximum of 0.5 AMA PRA Category 1 Credit™.
- Read the following information before entering the educational activity.
- Complete the Pretest.
- Study the educational activity.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
CME credit will be granted for only 1 form of participation, either online or via the printed publication.
You will be asked to login
or create an account.